Noida: Jubilant Biosys Innovative Research Services Private Limited, Singapore (JBIRSPL), a subsidiary of Jubilant Biosys Limited, a wholly-owned subsidiary of Jubilant Pharmova Limited, has entered into definitive agreements with Pierre Fabre SA and its affiliates (“PF”) for a transaction under which JBIRSPL will acquire 80% of the equity capital in Jasmin (the new company formed by PF in France, as Société par Actions Simplifié (SAS)), while the remaining 20% will remain with PF.
Upon closing of the transaction, Jasmin will acquire Pierre Fabre’s R&D Centre (including the R&D site and R&D activities) at Saint-Julien-en-Genevois, France, and JBIRSPL will also execute a shareholders agreement and other transition agreements with PF.
Strategic Rationale
This strategic agreement will enable Jubilant Biosys Limited to expand its footprint in Europe in areas such as biologics (mAbs) and antibody drug conjugates (ADC), in addition to its existing services including integrated drug discovery services from India
- Expands Jubilant’s addressable market in the fast-growing (20%+ CAGR) ADC/XDC segment: Expands Jubilant’s addressable market in ADC CDMO to $1.4 billion. The next-generation XDC pipeline is also growing rapidly
- Enhances Jubilant Biosys Limited’s domain expertise in ADC with expanded chemistry capabilities: Complements Jubilant Biosys Limited’s payload expertise with payload-linker synthesis, bioconjugation and analytical services
- PF team has deep ADC/XDC expertise: Core team with decades of ADC experience, history of successfully delivering multiple clinical candidates
- Provides strategic footprint in the EU: Opportunity to significantly expand our customer relationships with large pharmaceutical companies due to proximity to EU/US markets that have a preference for local CRO interactions
- Brings together a complementary innovator customer base: The collaboration will help create significant cross-selling potential for customer bases across small to medium biotech and large innovator pharma
